News

APL 130277 is a reformulation of the currently marketed injection into an oral formulation that will follow an expedited clinical development path of 18-24 months based on the

Pfizer has begun the process of preparing a marketing authorization application (MAA) for submission to the European Medicine Agency (EMA) for Bosutinib as a treatment option for patients

Rituxan/MabThera is a therapeutic antibody that binds to a particular protein – the CD20 antigen – on the surface of normal and malignant B-cells. It then recruits the

Delcath’s proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic

Zometa, an intravenous bisphosphonate, is indicated for the prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumor-induced hypercalcemia) in patients with

Fraunhofer said that the purpose of the Phase 1 study is to determine safety of the new vaccine along with appropriate dosage levels. In the trial, the new

The single-arm pivotal trial assessed efficacy and safety of single-agent brentuximab vedotin in relapsed or refractory, post-autologous stem cell transplant (ASCT) Hodgkin lymphoma patients. Brentuximab vedotin is an

rFVIIIFc is a fully-recombinant clotting factor developed using Biogen Idec‘s novel and proprietary monomeric Fc fusion technology. The technology makes use of a natural mechanism that recycles rFVIIIFc

O2h is a discovery services company co-located in Cambridge, UK and Ahmedabad, India. The Indian operations provide chemistry expertise while UK office provides project management support. Phytopharm CEO